Matches in SemOpenAlex for { <https://semopenalex.org/work/W4238735537> ?p ?o ?g. }
Showing items 1 to 91 of
91
with 100 items per page.
- W4238735537 endingPage "vi155" @default.
- W4238735537 startingPage "vi155" @default.
- W4238735537 abstract "Inhibition of mTOR in addition to EGFR may overcome upstream resistance to EGFR inhibitors in CRC. This phase II study evaluated the efficacy and safety of the combination of irinotecan, panitumumab and everolimus based on dosing established in the previously reported phase Ib study (Townsend JCO 2013 (suppl;abstr 14506)). Patients with KRAS exon 2 WT mCRC following failure of fluoropyrimidine based therapy received IV irinotecan (200mg/m2), panitumumab (6mg/kg) every 2 weeks, and everolimus 5mg orally alternate days throughout a 14 day cycle. The primary endpoint was response rate (RR) and secondary endpoints were safety and tolerability, progression free survival (PFS) and overall survival (OS). Survival outcomes were calculated using Kaplan-Meier method and all results analysed as intention to treat. 40 patients were enrolled in the expansion phase. Median age 60 years (37-76), M/F 26/14, ECOG 0/1/2 18/21/1, neutrophil/lymphocyte ratio >3 at baseline in 53%. The median number of cycles of the PIE combination received was 5 (range 0-28 cycles) and mean 8.2 cycles with 4 patients still on treatment. Grade 3 toxicities were diarrhoea 23%, mucositis 18%, rash 13%, fatigue 8%, dehydration 5%, neutropenia 20%, febrile neutropenia 8%, hypomagnesemia 20% and hypokalaemia 8%. Grade 4 toxicities were hypomagnesemia 5% and neutropenia 3%. The median relative dose intensity was 85%. 4 patients ceased everolimus within 30 days due to toxicity. RR was 45%, stable disease 45%, and disease progression 10%. 2 patients underwent subsequent liver resection. The median PFS was 5.6 months and median OS 10.8 months. The 12 month OS was 48% and 18 month OS 33%. This regimen has major toxicities of diarrhoea, mucositis and rash. The RR of 45% supports further study of this combination. Median OS was relatively short noting poor prognostic markers and analysis of extended RAS/BRAF is ongoing and will be presented." @default.
- W4238735537 created "2022-05-12" @default.
- W4238735537 creator A5029000771 @default.
- W4238735537 creator A5030183755 @default.
- W4238735537 creator A5033887180 @default.
- W4238735537 creator A5051472737 @default.
- W4238735537 creator A5054672072 @default.
- W4238735537 creator A5058526313 @default.
- W4238735537 creator A5061460550 @default.
- W4238735537 creator A5070238121 @default.
- W4238735537 creator A5080423970 @default.
- W4238735537 date "2016-10-01" @default.
- W4238735537 modified "2023-09-27" @default.
- W4238735537 title "A phase IB/II study of second-line therapy with panitumumab, irinotecan and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT)" @default.
- W4238735537 doi "https://doi.org/10.1093/annonc/mdw370.20" @default.
- W4238735537 hasPublicationYear "2016" @default.
- W4238735537 type Work @default.
- W4238735537 citedByCount "1" @default.
- W4238735537 countsByYear W42387355372017 @default.
- W4238735537 crossrefType "journal-article" @default.
- W4238735537 hasAuthorship W4238735537A5029000771 @default.
- W4238735537 hasAuthorship W4238735537A5030183755 @default.
- W4238735537 hasAuthorship W4238735537A5033887180 @default.
- W4238735537 hasAuthorship W4238735537A5051472737 @default.
- W4238735537 hasAuthorship W4238735537A5054672072 @default.
- W4238735537 hasAuthorship W4238735537A5058526313 @default.
- W4238735537 hasAuthorship W4238735537A5061460550 @default.
- W4238735537 hasAuthorship W4238735537A5070238121 @default.
- W4238735537 hasAuthorship W4238735537A5080423970 @default.
- W4238735537 hasBestOaLocation W42387355371 @default.
- W4238735537 hasConcept C121608353 @default.
- W4238735537 hasConcept C126322002 @default.
- W4238735537 hasConcept C141071460 @default.
- W4238735537 hasConcept C143998085 @default.
- W4238735537 hasConcept C197934379 @default.
- W4238735537 hasConcept C203092338 @default.
- W4238735537 hasConcept C2776694085 @default.
- W4238735537 hasConcept C2777063308 @default.
- W4238735537 hasConcept C2778332735 @default.
- W4238735537 hasConcept C2778375690 @default.
- W4238735537 hasConcept C2778496288 @default.
- W4238735537 hasConcept C2778850193 @default.
- W4238735537 hasConcept C2779699572 @default.
- W4238735537 hasConcept C2780259306 @default.
- W4238735537 hasConcept C2780739268 @default.
- W4238735537 hasConcept C2781187634 @default.
- W4238735537 hasConcept C31760486 @default.
- W4238735537 hasConcept C526805850 @default.
- W4238735537 hasConcept C535046627 @default.
- W4238735537 hasConcept C71924100 @default.
- W4238735537 hasConcept C90924648 @default.
- W4238735537 hasConceptScore W4238735537C121608353 @default.
- W4238735537 hasConceptScore W4238735537C126322002 @default.
- W4238735537 hasConceptScore W4238735537C141071460 @default.
- W4238735537 hasConceptScore W4238735537C143998085 @default.
- W4238735537 hasConceptScore W4238735537C197934379 @default.
- W4238735537 hasConceptScore W4238735537C203092338 @default.
- W4238735537 hasConceptScore W4238735537C2776694085 @default.
- W4238735537 hasConceptScore W4238735537C2777063308 @default.
- W4238735537 hasConceptScore W4238735537C2778332735 @default.
- W4238735537 hasConceptScore W4238735537C2778375690 @default.
- W4238735537 hasConceptScore W4238735537C2778496288 @default.
- W4238735537 hasConceptScore W4238735537C2778850193 @default.
- W4238735537 hasConceptScore W4238735537C2779699572 @default.
- W4238735537 hasConceptScore W4238735537C2780259306 @default.
- W4238735537 hasConceptScore W4238735537C2780739268 @default.
- W4238735537 hasConceptScore W4238735537C2781187634 @default.
- W4238735537 hasConceptScore W4238735537C31760486 @default.
- W4238735537 hasConceptScore W4238735537C526805850 @default.
- W4238735537 hasConceptScore W4238735537C535046627 @default.
- W4238735537 hasConceptScore W4238735537C71924100 @default.
- W4238735537 hasConceptScore W4238735537C90924648 @default.
- W4238735537 hasLocation W42387355371 @default.
- W4238735537 hasOpenAccess W4238735537 @default.
- W4238735537 hasPrimaryLocation W42387355371 @default.
- W4238735537 hasRelatedWork W1982236564 @default.
- W4238735537 hasRelatedWork W1982876272 @default.
- W4238735537 hasRelatedWork W2145857211 @default.
- W4238735537 hasRelatedWork W2253498715 @default.
- W4238735537 hasRelatedWork W2503036974 @default.
- W4238735537 hasRelatedWork W2590444302 @default.
- W4238735537 hasRelatedWork W2778209820 @default.
- W4238735537 hasRelatedWork W2801056424 @default.
- W4238735537 hasRelatedWork W2911646528 @default.
- W4238735537 hasRelatedWork W4226504180 @default.
- W4238735537 hasVolume "27" @default.
- W4238735537 isParatext "false" @default.
- W4238735537 isRetracted "false" @default.
- W4238735537 workType "article" @default.